Undervalued Small Caps With Insider Buying

Results

69

28 new

Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.

69 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
	UNB	US$24.35	3.6%	-10.5%	US$109.3m	n/a	1.2	n/a	5.9%	Banks
	AUBN	US$26.15	-0.4%	-2.8%	US$91.3m	n/a	1.0	n/a	4.1%	Banks
	MDV	US$18.05	6.5%	16.0%	US$217.0m	US$18.67	1.2	149.5%	6.6%	Real Estate
	BOTJ	US$27.51	1.5%	95.8%	US$124.1m	n/a	1.5	n/a	1.5%	Banks
	GABC New	US$50.88	-0.3%	26.3%	US$1.9b	US$56.20	1.6	5.6%	2.4%	Banks
	KINS	US$19.62	-3.7%	26.0%	US$276.1m	US$21.50	8.0	16.7%	1.2%	Insurance
	CBNA New	US$48.50	1.9%	77.0%	US$316.4m	US$49.00	1.7	10.1%	n/a	Banks
	ORN New	US$9.93	-3.9%	44.1%	US$395.6m	US$15.32	111.6	74.8%	n/a	Capital Goods
	ILPT	US$9.07	3.7%	54.0%	US$590.7m	US$11.17	1.3	20.7%	4.4%	Real Estate
	ENOV New	US$24.69	-18.2%	-16.6%	US$1.4b	US$41.25	0.6	145.8%	n/a	Healthcare
	BMRC	US$28.53	-2.1%	21.9%	US$455.3m	US$31.80	1.2	102.5%	3.5%	Banks
	SMWB	US$8.79	18.1%	4.3%	US$635.1m	US$9.00	2.7	128.8%	n/a	Software
	CDNL New	US$35.97	-43.1%	n/a	US$1.8b	US$61.00	1.3	n/a	n/a	Capital Goods
	HQI New	US$16.64	29.9%	71.9%	US$238.8m	US$19.00	27.4	10.4%	1.4%	Commercial Services
	RCEL	US$8.12	81.7%	41.0%	US$253.6m	US$9.03	3.3	69.9%	n/a	Pharmaceuticals & Biotech
	SHBI	US$24.01	-1.5%	48.3%	US$795.3m	US$25.75	1.3	8.1%	2.3%	Banks
	FRST	US$16.33	-0.4%	42.0%	US$399.5m	US$18.63	0.9	-3.0%	2.4%	Banks
	ERII	US$7.72	-15.4%	-46.0%	US$407.8m	US$9.33	25.7	27.1%	n/a	Capital Goods
	PMTS New	US$30.50	33.1%	89.9%	US$329.7m	US$32.50	25.6	46.8%	0%	Tech
	KRO	US$7.86	26.6%	30.3%	US$963.4m	US$6.50	0.5	5.4%	2.5%	Materials
	ALRS New	US$33.84	0.2%	54.1%	US$832.8m	US$35.40	30.6	40.6%	2.6%	Diversified Financials
	ANIK New	US$22.03	14.8%	142.6%	US$284.1m	US$21.00	2.4	112.3%	n/a	Pharmaceuticals & Biotech
	MRBK	US$19.91	0.3%	31.0%	US$236.3m	US$23.50	1.2	23.4%	2.8%	Banks
	CMTV New	US$39.60	-2.6%	72.4%	US$228.5m	n/a	1.8	n/a	2.5%	Banks

Page 1 of 2